Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Management
Scientific Advisory Board
Corporate Directory
Corporate Governance
Pipeline
Background - FAK
Background - Fibrotic Cancers
Background - Fibrosis
Our FAK Inhibitors
Investor Information
Welcome
Investor Fact Sheet
Investor Presentation
Media
Research Reports
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Annual Reports
Half Yearly Reports
Quarterly Reports
Contact Us
Contact Us
Email Alerts
Investor Information
Home
>
Investor Information
>
Media
Welcome
Investor Fact Sheet
Investor Presentation
Media
Research Reports
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Media
14-Oct-2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
9-Oct-2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
9-Oct-2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
